Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model

International Journal of Radiation Oncology Biology Physics

Volumn 50, Issue 2, 2001, Pages 473-478

  Symon, Zvi ^a   Levi, Micha ^a   Ensminger, William D ^a   Smith, David E ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amifostine; Liver neoplasms; Micronucleus assay; Radioprotection

Indexed keywords

ASSAYS; ELECTROCHEMISTRY; PATIENT MONITORING; RADIATION; TISSUE; TUMORS;

LIVER CANCER;

ONCOLOGY;

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; DRUG METABOLITE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TISSUE LEVEL; ELECTROCHEMICAL DETECTION; FEMORAL VEIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INTRAVAGINAL DRUG ADMINISTRATION; LIVER CELL; LIVER TUMOR; MALE; MICRONUCLEUS TEST; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; RADIATION PROTECTION; RAT; TECHNIQUE;

AMIFOSTINE; ANALYSIS OF VARIANCE; ANIMALS; HEPATOCYTES; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MERCAPTOETHYLAMINES; MICRONUCLEUS TESTS; PORTAL VEIN; RADIATION-PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0035370755     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01522-X     Document Type: Article

References (36)

1. Lawrence T.S., Robertson J.M., Anscher M.S., Jirtle R.L., Ensminger W.D., Fajardo L.F. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 31:1995;1237-1248.
2. Lawrence T.S., Tesser R.J., ten Haken R.K. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int J Radiat Oncol Biol Phys. 19:1990;1041-1047.
3. Lawrence T.S., Ten Haken R.K., Kessler M.L., et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 23:1992;781-788.
4. McGinn C.J., Ten Haken R.K., Ensminger W.D., Walker S., Wang S., Lawrence T.S. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol. 16:1998;2246-2252.
5. Dawson L.A., McGinn C.J., Normolle D., et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 18:2000;2210-2218.
6. Milas L., Hunter N., Reid B.O., Thames H.D. Jr. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. Cancer Res. 42:1982;1888-1897.
7. Rasey J.S., Nelson N.J., Mahler P., Anderson K., Krohn K.A., Menard T. Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721 LD50 studies and 35S-WR-2721 biodistribution . Radiat Res. 97:1984;598-607.
8. Shaw L.M., Bonner H.S., Brown D.Q. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos. 22:1994;895-902.
9. Snyder R.D., Grdina D.J. Further evidence that the radioprotective aminothiol, WR-1065, catalytically inactivates mammalian topoisomerase II. Cancer Res. 60:2000;1186-1188.
10. Clement J.J., Johnson R.K. Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors. Int J Radiat Oncol Biol Phys. 8:1982;539-542.
11. Milas L., Hunter N., Ito H., Peters L.J. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721. Int J Radiat Oncol Biol Phys. 10:1984;41-48.
12. Dunn T.A., Schmoll H.J., Grunwald V., Bokemeyer C., Casper J. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs. 7:1996;795-799.
13. Grdina D.J., Hunter N., Kataoka Y., Murley J.S., Milas L. Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide. Semin Oncol. 26:1999;22-27.
14. Taylor C.W., Wang L.M., List A.F., et al. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer. 33:1997;1693-1698.
15. Yuhas J.M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 40:1980;1519-1524.
16. Calabro-Jones P.M., Aguilera J.A., Ward J.F., Smoluk G.D., Fahey R.C. Uptake of WR-2721 derivatives by cells in culture Identification of the transported form of the drug . Cancer Res. 48:1988;3634-3640.
17. Rasey J.S., Grunbaum Z., Krohn K.A., Menard T.W., Spence A.M. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913). Radiat Res. 102:1985;130-137.
18. Jirtle R.L., Pierce L.J., Crocker I.R., Strom S.C. Radiation protection of rat parenchymal hepatocytes with S-2-(3-aminopropylamino)ethylphosphorothioic acid. Radiother Oncol. 4:1985;231-237.
19. Jirtle RL, Ancher MS, Alati T. Radiation sensitivity of the liver. In: Lett JT and Altman, KI, editors. Advances in radiation biology. Vol. 14. San Diego: Academic Press Inc, 1990. p. 269-311.
20. Ensminger W.D., Rosowsky A., Raso V., et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res. 38:1978;3784-3792.
21. Wagner J.G., Gyves J.W., Stetson P.L., et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 46:1986;1499-1506.
22. Jansons R.A., Mosier H.D. Jr. A simplified method for chronic portal vein cannulation in the rat. Physiol Behav. 38:1986;739-741.
23. Deschenes J., Valet J.P., Marceau N. Hepatocytes from newborn and weanling rats in monolayer culture Isolation by perfusion, fibronectin-mediated adhesion, spreading, and functional activities . In Vitro. 16:1980;722-730.
24. Alati T., Eckl P., Jirtle R.L. An in vitro micronucleus assay for determining the radiosensitivity of hepatocytes. Radiat Res. 119:1989;562-568.
25. Shaw L.M., Turrisi A.T., Glover D.J., et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 12:1986;1501-1504.
26. Schuchter L.M. Guidelines for the administration of amifostine. Semin Oncol. 23:1996;40-43.
27. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 17:1999;3333-3355.
28. Joshi G.P., Nelson W.J., Revell S.H., Shaw C.A. X-ray-induced chromosome damage in live mammalian cells and improved measurements of its effects on their colony-forming ability. Int J Radiat Biol Relat Stud Phys Chem Med. 41:1982;161-181.
29. Midander J., Revesz L. The frequency of micronuclei as a measure of cell survival in irradiated cell populations. Int J Radiat Biol Relat Stud Phys Chem Med. 38:1980;237-242.
30. Smoluk G.D., Fahey R.C., Calabro-Jones P.M., Aguilera J.A., Ward J.F. Radioprotection of cells in culture by WR-2721 and derivatives Form of the drug responsible for protection . Cancer Res. 48:1988;3641-3647.
31. Murray D., Rosenberg E., Allalunis-Turner M.J. Protection of human tumor cells of differing radiosensitivity by WR-1065. Radiat Res. 154:2000;159-162.
32. Moulder J.E., Lo P.S., Fischer J.J. Effect of the radioprotective drugs MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat. Cancer Treat Rep. 61:1977;825-833.
33. Utley J.F., Phillips T.L., Kane L.J., Wharam M.D., Wara W.M. Differential radioprotection of euoxic and hypoxic mouse mammary tumors by a thiophosphate compound. Radiology. 110:1974;213-216.
34. Levi M, Knol JA, DeRemer SJ; et al. Regional pharmacokinetics of amifostine in dogs: Role of the liver, gastrointestinal tract, lungs and kidneys. Pharm Sci 2000;1(Suppl).
35. Kuan H.Y., Smith D.E., Ensminger W.D., et al. Regional pharmacokinetics of 5-fluorouracil in dogs Role of the liver, gastrointestinal tract, and lungs . Cancer Res. 58:1998;1688-1694.
36. Andreopoulos D., Schleicher U.M., Cotarelo C.L., Hand S., Ammon J. Radioprotection of human endothelial cells with amifostine. Strahlenther Onkol. 175:(Suppl. 4):1999;34-36.